Group, H. C., Jiang, L., Hopewell, J., Collins, R., & Armitage, J. (2013). HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: Trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Oxford University Press.
Cytowanie według stylu Chicago (wyd. 17)Group, HPS2-THRIVE Collaborative, L. Jiang, J. Hopewell, R. Collins, i J. Armitage. HPS2-THRIVE Randomized Placebo-controlled Trial in 25 673 High-risk Patients of ER Niacin/laropiprant: Trial Design, Pre-specified Muscle and Liver Outcomes, and Reasons for Stopping Study Treatment. Oxford University Press, 2013.
Cytowanie według stylu MLA (wyd. 9)Group, HPS2-THRIVE Collaborative, et al. HPS2-THRIVE Randomized Placebo-controlled Trial in 25 673 High-risk Patients of ER Niacin/laropiprant: Trial Design, Pre-specified Muscle and Liver Outcomes, and Reasons for Stopping Study Treatment. Oxford University Press, 2013.